Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase III Trial of Immunotherapy Based Combination Therapy With or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (PROBE TRIAL)
NCT Number:
NCT04510597
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Kidney
Study Objectives:
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Study Documents
(MUSC NetID required for document access)